The unique characteristics and manufacturing processes of therapeutic
biological products and drug compounds lays the framework for the differences
in regulatory requirements for getting into the marketplace. While, biologics and drugs are both used for the same purposes — to
treat, prevent, and cure diseases — biological products are much more complex
in nature. By comparison, common drug compounds are relatively simple.
What exactly is a biological product?
Biological products are comprised of large and
complex protein structures that are primarily derived from living material,
including human, animal, and microorganisms. Proteins are often
post-transcriptional modified, including glycosylation, oxidation, deamidation,
and this has a profound effect on protein properties. As seen in the figure below, this contrast
with conventional drug compounds, such as aspirin, that have a smaller
molecular weight and are chemically synthesized. Peptides can fall into either regulatory
category and are comprised of amino acids just like a protein, but peptides are
smaller.
The vast
differences in complexity and size are depicted in this figure.
Defining biological products and drug compounds is the
first step to understanding the common and unique regulatory requirements for
each. FDA’s definition is the only one that matters for the purpose of
obtaining marketing approval in the United States, and the definition for
biologics is in a transition period.
Hang in there while we get to the
precise definitions as we transverse the regulatory pathways described in the
next section.
Acronym
Full Name
BLA
Biologic License Application
BPCI
Biologics Price Competition and Innovation Act of 2009
The FDA Has Separate Agencies with Oversight for Biologics and Drugs.
CBER and CDER
To deal with products of dramatically different composition
and manufacturing protocols, the FDA created two independent specialized
centers with premarket review and oversight responsibilities: The Center for
Biologics Evaluation and Research (CBER) and The Center for Drug Evaluation and
Research (CDER).
FDA defines which center a product is funneled into based
on its definitions. While there has been some overlap in regulatory oversight
for biologics and drugs under the current regulations, new guidelines will take
precedence next year.
FD&C Act and PHS Act
Therapeutic biological products are a subset of drugs and
thus regulated by the Food Drug and Cosmetic Act (FD&C Act) just like
common drugs. In addition, biological products are regulated by the Public
Health Service Act (PHS Act) due to their complex manufacturing processes.
Current center responsibilities are listed
below flowed by the newest changes.
Drug Compounds
CDER traditionally is the only center with regulatory
oversight of drug products.
Biological Products
Up until March 22nd of 2020, both CBER and CDER
have regulatory responsibility for therapeutic biological products under the
FD&C Act and PHS Act. CDER currently regulates the following categories of therapeutic biological
products.
Monoclonal antibodies for in vivo use
Most proteins intended for therapeutic use,
including cytokines (e.g., interferons), enzymes (e.g., thrombolytics), and
other novel proteins, except for those that are specifically assigned to CBER
(e.g., vaccines and blood products). This category includes therapeutic
proteins derived from plants, animals, humans, or microorganisms, and
recombinant versions of these products. Exceptions to this rule are coagulation
factors (both recombinant and human-plasma derived).
Immunomodulators (non-vaccine and
non-allergenic products intended to treat disease by inhibiting or
down-regulating a pre-existing, pathological immune response).
Immunomodulators
(non-vaccine and non-allergenic products intended to treat disease by
inhibiting or down-regulating a pre-existing, pathological immune response).
Growth factors,
cytokines, and monoclonal antibodies intended to mobilize, stimulate, decrease,
or otherwise alter the production of hematopoietic cells in vivo.
New Definition of Biological Product
The definition of biologics changed with the newest amendments
to the Biologics Price Competition and Innovation Act of 2009 (BPCI
Act).
The BPCI Act was enacted on March 23rd, 2010, and 2020 marks the end
of the 10-year transition period to allow sponsors time to make a seamless
transition between the CDER and CBER regulatory agencies.
The BPCI Act amends section 351(i) of the PHS Act modifying the definition of a biological product to include a “protein (except any chemically synthesized polypeptide).
Here is the FDA’s definition of these keywords in section
351(1) of the PHS Act:
Biological Product – “…a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.”
Protein –
“any alpha amino acid polymer with a specific defined sequence that is greater
than 40 amino acids in size…:”
Chemically Synthesized
Polypeptide – “…the term chemically synthesized
polypeptide would mean any alpha amino acid polymer that: (1) is made
entirely by chemical synthesis and (2) is greater than 40 amino acids but less
than 100 amino acids in size.”
Peptide – “…a
polymer composed of 40 or fewer amino acids…”
BLA and NDA Applications for Marketing Approval
As we will discuss in an upcoming post, both biologics and drugs must first go through a rigorous process to determine their safety and efficacy in humans before they can be sold in interstate commerce. This involves basic research and subsequent supporting clinical trials in humans. Approval of the relevant Biological Licensing Application (BLA) or New Drug Application (NDA) is the last major hurdle to getting a biologic or drug approved for marketing in the United States.
The BLA / NDA is the formal process by which a sponsor applies to FDA asking for permission to approve a new biologic or pharmaceutical for sale and marketing in the United States (21 CFR 601.2). The application tells the products full story of development and supports its use for a specific disease condition. The IND application precedes the BLA / NDA application, and the IND is actually part of the BLA / NDA as it is the living document that is kept up to date throughout the clinical evaluation process.
A key consideration is that an NDA needs to show that the
drug is “safe and effective,” while the BLA is required to ensure the licensed
biological product’s “safety, purity, and potency.”
The FDA ultimately makes the decision to either “approve” or “not to approve” the product based on the product’s safety and efficacy in the population for its intended use as outlined in the application. Thus, having a highly organized and well written BLA / NDA is critical for getting a product to market. Many sponsors utilize a CRO to facilitate faster market approval.
Be aware that starting March 23rd,
2020, the BPCI Act requires that approval of all “biological products” needs to
be submitted and approved through a BLA. After this date, even
pending or tentatively approved 505(b)2 applications will not be approved by the
FDA, at least according to the current guidance document.
Therefore, the FDA recommends sponsors that are unable to
complete the NDA by the transition deadline, to start down the BLA pathway now.
Failure to receive final approval by the 2020 deadline for applications in
progress will likely have a significant impact on proposed protein products.
Here is FDA’s preliminary list of
approved biological products that will be deemed BLAs on March 23, 2020.
The Role of RA in the Clinical and Performance Evaluation Process: Key Strategies to Support Project Success
Scoping Your MDR and IVDR Writing Projects - The Forgotten Step
Ask the Writers: A Comparison of Critical Elements of the SVR versus the CER State-of-the-Art and Best Practice Writing Strategies
[Ask the Expert] Tips For How to Avoid Common Notified Body Review Findings
How to Establish the Competitive Landscape Within the Scientific Validity Report
IVD Deep Dive Series Part 2
Clinical Evaluation: Measurable Objectives and Acceptance Criteria to Verify Device Safety and Performance
This white paper outlines strategies for the verification of device safety and performance as well as tips to define parameters to determine the acceptability of benefit-risk.
Post-Market Literature Surveillance: Systematic Literature Review and Case Study
[Ask the Expert] Safety and Performance Measures and Acceptance Criteria for MDR
[Ask the Expert] Safety and Performance Measures and Acceptance Criteria for IVDR
[Ask the Expert] Clinical Data for IVD: What Is It and How Do I Find It?
IVD Deep Dive Series Part 1
IVDR Essentials: Performance Evaluation Report - Early Planning and Preparation
How to Establish the State of the Art Within the Scientific Validity Report
How to Establish the State-of-the-Art Within the Scientific Validity Report
Clinical Evaluation: Measurable Objectives and Acceptance Criteria to Verify Device Safety and Performance
[Ask the Expert] The Importance of Clinical Data: Sources of Data, Literature Searches, Weighting & Appraisal and Effective Presentation in your CER or PER
[Ask the Expert] Clinical Evaluation: Measurable Objectives and Acceptance Criteria to Verify Device Safety and Performance
[Ask the Expert] Systematic Literature Review: What is it and why is it so important?
How to Establish the Competitive Landscape Within the Scientific Validity Report
[Ask the Expert] Safety and Performance Measures and Acceptance Criteria
How to Establish the State-of-the-Art Within the Scientific Validity Report
[Ask the Expert] Performance Evaluation Report
[Ask the Expert] Performance Evaluation Report
[Ask the Expert] The Importance of Clinical Data: Sources of Data, Literature Searches, Weighting & Appraisal and Effective Presentation in your CER or PER
[Ask the Expert] Safety and Performance Measures and Acceptance Criteria
A Practical Guide: Conducting Systematic Literature Reviews in Support of IVDR Readiness [Free Webinar]
In this practical presentation, Criterion Edge breaks down the steps of the SLR process and takes a wholistic approach to conducting an IVDR-compliant SLR. Using case studies, the presentation illustrates the effective use of SLR-derived data to develop the Scientific Validity Report (SVR) and the Clinical Performance Report (CPR).
Systematic Literature Review: Empower Data-Driven Decisions White Paper
This white paper is a companion piece to our popular webinar where we share our insights on using the Systematic
Literature Review (SLR) to Empower Data-Driven Decisions in your Organization.
Systematic Literature Review: How to Empower Data-Driven Decision Making [Free Webinar]
In this webinar, we share the process of systematic literature review, and discuss the tools and best practices for creating a methodologically-sound systematic literature review.
State of the Art: Building a Solid Foundation for your PER to Support IVDR Readiness
In this webinar, Dr. Sarah Chavez provides an overview of the State of the Art section, and explains how it fits into the overall process of writing a successful, IVDR-compliant Performance Evaluation Report (PER) in a reasonable time frame. A complete readiness assessment and gap analysis will help you identify critical resources, feeder documents, and expertise needed to establish that your IVD may be considered “state-of-the-art.” Ultimately, knowing what the Notified Body expects to see will help you avoid project delays and discover efficiencies in the SOA development process.
A Practical Guide: Conducting Systematic Literature Reviews for IVDR Readiness
This white paper is a companion piece to our popular webinar where we break down the steps of the systematic literature review (SLR) process and take a wholistic approach to conducting an In Vitro Diagnostic Regulation (IVDR)- compliant SLR.
State of the Art: Establishing a Solid Foundation for Your PERs to Encourage IVDR Readiness
This white paper is a companion piece to our popular webinar where we cover the state of the art process and how it
fits into the In Vitro Diagnostic Regulation (IVDR).
Sign Up to be Notified of Our Upcoming Webinars!
Schedule a Free Consult Today!
Fill out this form, or contact us at info@criterionedge.com, and we would be happy to answer any of your questions as well as book you an appointment to discuss your project needs during a time that works for you.
Are You Reg. Ready? Get your medical affairs team primed to manage new regulatory requirements
In this discussion, we provide an overview of how to plan and coordinate change within an organization to meet upcoming EU IVDR regulatory requirements. We will be highlighting key steps involved in helping medical affairs transition to a more rigorous regulatory environments, and how to evaluate talent gaps, team leadership composition, and process challenges of your product portfolio.
Effective Corporate Scientific Communications White Paper
This white paper is a companion piece to our popular webinar where we share some of the best approaches we have
discovered for Corporate Scientific Communication Strategies.
Driving Innovation to Success in the Market: Strategic Considerations
In this discussion, our panel of proven leaders discuss the key elements that support and propel the innovation process in the medical device, pharmaceutical, and IVD industries. We will be highlighting key areas of the process, important players in the pathway to the market, and how successful innovations spawn new innovations in new markets such as the digital health space, and more.
Hidden Traps That Will Derail Your PER White Paper
This white paper is a companion piece to our popular webinar that uncovers what we have learned from our experience in writing Medical Device Regulation (MDR)-compliant Clinical Evaluation Reports (CERs), and how urgently applicable some of these key learnings are in preparing a robust Performance Evaluation Report (PER).
Hidden Traps That Will Derail Your CER White Paper
This white paper is a companion piece to our popular webinar where we share some of the biggest issues we have discovered when starting a Clinical Evaluation Report (CER) project, and how to anticipate and avoid project delays.
How to Assess Your CER for MDR-Readiness Part 2
This companion piece to our popular webinar discusses strategies for assessing key components of your CER like clinical data sources and risk-benefit analysis.
How to Assess Your CER for MDR-Readiness Part 1
This white paper outlines strategies to assess your CER including state of the art, safety and performance criteria, equivalence and systematic literature review.
Leveraging the MDR experience for IVDR: Tips for Successful Performance Evaluation and PMS/PMPF Processes [Free Webinar]
Have the IVDR Performance Evaluation and Post Market Surveillance requirements got you tied up in knots? Where do you start? What does the end product look like? We are joined by the VP of Regulatory, Quality, and Clinical from Nextern, a collaborative medical device company bringing unmatched core competence in medical device product design and development. Criterion Edge’s President Laurie Mitchell will lead a discussion of their experiences supporting clients through MDR and IVDR requirements.
Effective Corporate Scientific Communication: Strategies to Support your Corporate Narrative and Maximize the Real-World Impact of your Data [Free Webinar]
In this practical presentation, President Laurie Mitchell will: 1) discuss how an effective scientific communication plan is an important marketing tool for an organization, and 2) present five strategies to ensure your corporate objectives are supported and maximize the real-world impact of your data. Join us to learn how this applies to your organization and how to implement these strategies into your current processes.
Hidden Traps That Derail PER Preparedness: Lessons Learned from the MDR-Compliant CER Writing Experience [Free Webinar]
In this practical presentation, Criterion Edge uncovers what we have learned from our experience in writing MDR-compliant CERs, and how urgently applicable some of these key learnings are in preparing a robust Performance Evaluation Report (PER).
Hidden Traps That Can Derail Your CER: Answer These Critical Questions Before You Start Writing [Free Webinar]
As we all know, the MDR has significantly increased both the quality and quantity of inputs needed to complete a CER, needing more up-front planning than the reports have in the past. Based on our experiences with clients both large and small, our President, Laurie Mitchell, shares some of the biggest issues we have discovered when starting an MDR CER project. Laurie also reveals some of the most successful strategies in addressing these issues, up-front and early.
How to Assess Your CER for MDR Readiness, Part 2 [Free Webinar]
In this second installment of our 2-part webinar series, Criterion Edge shares practical presentation to help you assess your CER through the critical lens of a writer and identify possible gaps for mitigation before prior to submission to regulatory authorities.
Systematic Literature Review: How to Empower Data-Driven Decision Making [Free Webinar]
In this webinar, we share the process of systematic literature review, and discuss the tools and best practices for creating a methodologically-sound systematic literature review.
Experience and Scalability
Watch this video to learn how Criterion Edge is different from the rest.
5 Key Questions to Help Manage Your Budget
This infographic goes through 5 key questions to go through in order to control your budget.
Examining the Implications of the MDR on Data Management
Leading industry experts come together to discuss how the MDR affects data management within their respective units.
MedDev 2.7/1 Guideline: Equivalence and Risk/Benefit Profile
This report clarifies the modifications to the equivalence guidelines in MEDDEV 2.7/1 and Quality Management Systems (QMS) ISO 13485 standard to help develop strategies.
MedDev 2.7/1 Guideline: Qualifications of Evaluators and Scientific Validity
This gap analysis addresses key revisions to evaluator qualifications and scientific validity in the Clinical Evaluation (CE) MEDDEV guideline rev.4.
MedDev 2.7/1 Guideline: More Clinical Evaluations?
The changes to 2.7/1 rev. 4 suggest the need to submit more frequent CERs to regulatory authorities, however, strategies will be discussed for managing the increased requirements.
Data Mining: New Initiatives on Health Care Data that Manufacturers Should be Watching
Every time a healthcare provider makes a notation in the medical chart, a significant and valuable piece of data has been created. This paper discusses the implications of this.
10 Strategies to Build Efficiencies in your Regulatory Writing Process
This piece discusses 10 key strategies to building an efficient regulatory writing process.
State of the Art: Best Practices and Literature Review Using DistillerSR
In this paper, we discuss a prominent clarification on the MEDDEV 2.7.1 rev 4, establishing the “state of the art” section.
Q&A Follow-Up: How to Assess Your CER for MDR Readiness, Part 1 [Free Webinar]
The overwhelming turnout at the ‘How to Assess Your CER for MDR Readiness, Part 1’ prompted us to host a live Q+A session where President Laurie Mitchell exclusively answers all your questions.
Systematic Literature Review To Help Meet MDR Requirements [Free Webinar]
President Laurie Mitchell returns to continue sharing more about the importance of the systematic literature review.
State of the Art Literature Review for EU MDR Compliance: How To Get It Right [Free Webinar]
Establishing and defining state of the art for a medical device is no longer an isolated task – it supports the entire Clinical Evaluation Report (CER). Multiple sections of the MEDDEV 2.7/1 rev 4 compliant CER need to be supported by state of the art data, including safety and performance, risk management, and equivalence.
How to Assess Your CER for MDR Readiness, Part 1 [Free Webinar]
In this first installment of a 2-part webinar series, Criterion Edge will present strategies for assessing key components of your CER (or CER template) for possible misalignment with significant and applicable MDR requirements.
Intro to Adverse Event Reviews [Free Webinar]
In this webinar, President Laurie Mitchell discusses why safety reviews are essential in the entire life cycle of product development.
Advantages to Technologies Supporting Endpoint Adjudication [Free Webinar]
Kyoko Hattori from Criterion Edge returns to discuss best practices for managing the adjudication process in-house, and Brian Kelly from AG Mednet will share how the “JUDI” platform can simplify the management of adjudication.
Endpoint Adjudication by the Clinical Endpoints Committee (CEC) [Free Webinar]
In this webinar, learn about CECs, familiarization with regulatory guidance, decision factors leading to use of a CEC, and much more.
Privacy Overview
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
3rd Party Cookies
This website uses Google Tag Manager and Pardot's tracking features to collect information such as the number of visitors to the site, and the most popular pages. Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!